1+ week, 4+ day ago   (509+ words) 1. Current evidence does not support a class-wide amputation risk. While CANVAS raised concerns about canagliflozin, subsequent randomized trials, observational studies, and FDA review have not demonstrated a consistent amputation signal across the SGLT2 inhibitor class. How should podiatrists interpret the current…...

2+ week, 2+ day ago   (839+ words) Andrew Hahn, MD, MD Anderson Cancer Center, Houston, Texas, presents a case of de novo metastatic prostate cancer to illustrate how comprehensive molecular profiling can inform upfront treatment selection. Hi, my name is Andy Hahn, I'm an assistant professor of…...

1+ mon, 5+ day ago   (552+ words) HMP Global Learning Network Defining Optimal Medical Therapy for CLTI in 2026 On Friday morning at the Amputation Prevention Symposium, Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM, presented a review of the evidence supporting contemporary medical management for patients…...

1+ mon, 2+ week ago   (306+ words) Harold Nathan Tan, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses findings from a retrospective analysis evaluating early-phase immunotherapy trials in patients with recurrent or metastatic head and neck squamous cell carcinoma. Good afternoon, everyone, I’m…...

1+ mon, 2+ week ago   (218+ words) Brigitta Baumert, MD, PhD, Haaglanden Medical Center, The Hague, Netherlands, discusses long-term findings from the phase 3 EORTC 22033-26033 trial comparing upfront radiotherapy with dose-dense temozolomide in patients with clinically high-risk low-grade glioma. Hello, my name is Brigitta Baumert, and I am…...

1+ mon, 2+ week ago   (719+ words) HMP Global Learning Network Insights from the ESMO Gastrointestinal Cancers Congress Dual RAS Inhibition Demonstrates Promising Activity in KRAS G12D-Mutated Metastatic Pancreatic Cancer - Design/Population: This phase 1 study evaluated the combination of the KRAS G12D-selective RAS(ON) inhibitor zoldonrasib and…...

1+ mon, 3+ week ago   (303+ words) Arndt Vogel, MD, University of Toronto, Canada, discusses results from the phase 2 IMMUNIB trial evaluating first-line lenvatinib plus nivolumab in patients with unresectable hepatocellular carcinoma and the potential role of molecular biomarkers in identifying patients most likely to benefit from…...

1+ mon, 3+ week ago   (23+ words) HMP Global Learning Network...

1+ mon, 3+ week ago   (184+ words) Caitlin Costello: Great. So, a couple of takeaways I heard today are referral readiness, the importance of the timeline, and being prepared to anticipate what's coming and what may create barriers, so we can get our patients to CAR T-cells…...

1+ mon, 3+ week ago   (15+ words) HMP Global Learning Network...